1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,900 | 12,100 | 31.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.09. | Burning Rock Biotech Limited: Burning Rock's OncoGuide OncoScreen Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer | 2 | GlobeNewswire (USA) | ||
| 08.09. | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| BURNING ROCK BIOTECH Aktie jetzt für 0€ handeln | |||||
| 08.09. | Burning Rock Biotech Loss Shrinks In Q2 | - | RTTNews | ||
| 08.09. | Burning Rock Biotech Limited: Burning Rock Reports Second Quarter 2025 Financial Results | 328 | GlobeNewswire (Europe) | GUANGZHOU, China, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 06.06. | Burning Rock Biotech GAAP EPS of -$0.02, revenue of $18.34M | 1 | Seeking Alpha | ||
| 06.06. | Burning Rock Biotech Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 06.06. | Burning Rock Biotech Q1 Loss Narrows, Revenue Improves | 337 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) Friday reported loss before tax of RMB 13.28 million for the first quarter, significantly lower than RMB 121.37 million loss in the same... ► Artikel lesen | |
| 06.06. | Burning Rock Biotech Limited: Burning Rock Reports First Quarter 2025 Financial Results | 1.036 | GlobeNewswire (Europe) | GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 25.03. | Burning Rock Biotech Limited Q4 Loss Drops | 388 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) released Loss for fourth quarter of -RMB81.29 millionThe company's bottom line came in at -RMB81.29 million, or -RMB0.79 per share. This... ► Artikel lesen | |
| 25.03. | Burning Rock Biotech Limited: Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results | 312 | GlobeNewswire (Europe) | GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen | |
| 31.12.24 | Burning Rock Biotech Limited: Burning Rock Announces Results of 2024 Annual General Meeting | 415 | GlobeNewswire (Europe) | GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing... ► Artikel lesen | |
| 04.12.24 | Burning Rock Biotech Q3 Loss Narrows, Revenue Edges Up | 427 | AFX News | BEIJING (dpa-AFX) - Burning Rock Biotech Limited (BNR) Wednesday reported net loss of RMB35.75 million or $5.10 million for the third quarter, lower than RMB174.98 million loss in the same quarter... ► Artikel lesen | |
| 04.12.24 | Burning Rock Biotech Limited: Burning Rock Reports Third Quarter 2024 Financial Results | 231 | GlobeNewswire (Europe) | GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the "Company" or "Burning Rock"), a company focused on the application of next generation sequencing... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,22 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| MEDIGENE | 0,052 | -3,36 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 40,760 | +0,90 % | Dax lässt nach - Merck und Qiagen gefragt | Frankfurt/Main - Zum Wochenausklang hat der Dax nachgelassen. Zum Xetra-Handelsschluss wurde der Index mit 23.958 Punkten berechnet, ein Minus in Höhe von 0,7 Prozent im Vergleich zum Vortagesschluss.... ► Artikel lesen | |
| CUREVAC | 4,600 | -0,48 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,620 | -1,11 % | Watch Cigna, Moderna, Reddit, and More | ||
| VALNEVA | 4,012 | -0,20 % | Valneva-Aktie im Aufwind - Anleger hoffen auf positive Studiendaten und neue Kooperationen! | ||
| NOVAVAX | 7,227 | -0,92 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | +0,90 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 563,00 | -0,49 % | Paradigmenwechsel in der Glaukommedizin? NurExone erzielt dosisabhängige Wiederherstellung des Sehvermögens | ||
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,060 | -0,36 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| EDITAS MEDICINE | 2,717 | +1,19 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GENMAB | 247,20 | -0,24 % | H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB) | ||
| BIOCRYST PHARMACEUTICALS | 6,504 | +2,30 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen |
BURNING ROCK BIOTECH LTD ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 10,500 Euro und damit -8,70 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BURNING ROCK BIOTECH LTD ADR finden Sie auf Wallstreet Online.